VERTEX PHARMACEUTICALS INC / MA (VRTX)
Clinical trial NCT07161037 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. enrollment: 24 → 26 participants 3. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT07161037 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. enrollment: 24 → 26 participants 3. enrollment type: ESTIMATED → ACTUAL
Clinical trial NCT05929079 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. completion date: 2026-05-01 → 2026-06-16 3. primary completion date: 2026-05-01 → 2026-06-16 4. enrollment: 1000 → 1152 participants 5. enrollment type: ESTIMATED → ACTUAL
United Maritime Reports Second Quarter and First Half 2026 Financial Results
Share Buy Back - Share Purchase Mandate: Results of the Annual General Meeting - Proposed Renewal of the Share Buy-Back Mandate
Ideal Power to Host Second Quarter 2026 Results Conference Call on August 13, 2026 at 10:00 AM Eastern Time
Annual General Meeting :
L.B. Foster Company Announces Executive Officer Changes
Williams Improves on Key Sustainability Metrics Amid Rising Energy Demand
AiRWA Inc. Announces Completion of Acquisition of Best Life
Lifeway Foods® to Report Second Quarter 2026 Results on August 13, 2026